Stephen Ewald Net Worth

The estimated Net Worth of Stephen P Ewald is at least $7.39 Million dollars as of 29 February 2024. Mr. Ewald owns over 1,513 units of Medpace Inc stock worth over $4,463,498 and over the last 8 years he sold MEDP stock worth over $1,676,793. In addition, he makes $1,253,570 as General Counsel and Corporate Secretary at Medpace Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ewald MEDP stock SEC Form 4 insiders trading

Stephen has made over 13 trades of the Medpace Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,513 units of MEDP stock worth $597,922 on 29 February 2024.

The largest trade he's ever made was exercising 21,850 units of Medpace Inc stock on 27 July 2023 worth over $2,358,271. On average, Stephen trades about 4,684 units every 78 days since 2016. As of 29 February 2024 he still owns at least 13,341 units of Medpace Inc stock.

You can see the complete history of Mr. Ewald stock trades at the bottom of the page.

Stephen Ewald biography

Stephen P. Ewald J.D. serves as General Counsel, Corporate Secretary of the Company since June 2012. Mr. Ewald has also led the Human Resources department and other administrative functions since the third quarter of 2017. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as a director and chairman of the board of Mercy Health Foundation Board Cincinnati since 2015 and 2018, respectively, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.

What is the salary of Stephen Ewald?

As the General Counsel and Corporate Secretary of Medpace Inc, the total compensation of Stephen Ewald at Medpace Inc is $1,253,570. There are 3 executives at Medpace Inc getting paid more, with August Troendle having the highest compensation of $7,712,840.

How old is Stephen Ewald?

Stephen Ewald is 50, he's been the General Counsel and Corporate Secretary of Medpace Inc since 2012. There are 9 older and 5 younger executives at Medpace Inc. The oldest executive at Medpace Holdings Inc is Fred Davenport, 68, who is the Lead Independent Director.

What's Stephen Ewald's mailing address?

Stephen's mailing address filed with the SEC is C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.

Insiders trading at Medpace Inc

Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle, and Investors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.

What does Medpace Inc do?

a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.

Complete history of Mr. Ewald stock trades at Medpace Inc

Medpace Inc executives and stock owners

Medpace Inc executives and other stock owners filed with the SEC include:

• August Troendle,
  Chairman of the Board, President, Chief Executive Officer
• Susan Burwig,
  Executive Vice President - Operations
• Jesse Geiger,
  Chief Financial Officer, Chief Operating Officer - Laboratory Operations
• Stephen Ewald,
  General Counsel, Corporate Secretary
• Dr. August James Troendle M.D.,
  Chairman & CEO
• Susan E. Burwig,
  Exec. VP of Operations
• Jesse J. Geiger BBA, CPA,
  Pres
• Stephen P. Ewald,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Brian Carley,
  Independent Director
• Robert Kraft,
  Independent Director
• Fred Davenport,
  Lead Independent Director
• Cornelius McCarthy,
  Independent Director
• Ashley Keating,
  Independent Director
• Thomas King,
  Independent Director
• Brandon Ebken,
  Chief Information Officer
• John T. Wynne,
  Sr. VP of Commercial Operations & Clinical Pharmacology Unit
• Daniel O'Leary,
  Sr. VP of Medical Department
• Weimin Gai MS,
  Sr. VP of Biometrics
• Todd Meyers,
  VP of Bus. Devel. & Marketing
• Lauren Morris,
  Associate Director of Investors Relations
• Kevin M. Brady,
  CFO & Treasurer
• Penelope J Bucknell,
  VP, Human Resources
• Bruce Brown,
  Director
• Cinven Fund (No. 1) Limited...,
  
• Limited Partnership Medpace...,
  
• Dani S. Zander,
  Director
• Investors, Llc Medpace,
  10% owner
• Tom C King,
  Director
• Kevin M. Brady,
  CFO & Treasurer